Phase II Study of Paclitaxel and Cisplatin as Second-line Chemotherapy in Advanced Non-small Cell Lung Cancer.
10.12701/yujm.2004.21.2.198
- Author:
Yeoung Tae SEO
1
;
Bong Seog KIM
;
Ji Young GO
;
Dong Suk CHOI
;
Seong Ho CHOI
;
Hye Jin KIM
;
Young Mi AHN
;
Yong Ho ROH
;
Kyung Hee LEE
Author Information
1. Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Korea. seog@e-bohun.or.kr
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
Second-line chemotherapy;
Paclitaxel;
Cisplatin
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Cisplatin*;
Drug Therapy*;
Drug Therapy, Combination;
Humans;
Infusions, Intravenous;
Paclitaxel*
- From:Yeungnam University Journal of Medicine
2004;21(2):198-206
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: To evaluate the efficacy and safety of paclitaxel and cisplatin against advanced non-small cell lung cancer (NSCLC) as a second-line chemotherapy. SUBJECTS AND METHODS: Twenty-five patients were enrolled. The patients received 200 mg/m2 paclitaxel as a 3-hour intravenous infusion and 60 mg/m2 cisplatin as 30-minute intravenous infusion with vigorous hydration on day 1 every 28 days. The response was assessed every 2 cycles. RESULTS: All 25 patients were assessed for their response and toxicity. Partial responses were observed in 5 patients. The overall response rate was 20% (95% confidence interval, 4%~36%) and the median response duration was 4.5 (range, 2-11) months. The median time to progression was 3.3 (range, 0-14) months. The median overall survival of all patients was 7.4 (range, 1.3-39) months. The hematologic toxicities were minor and easily controlled. CONCLUSION: The combination chemotherapy of paclitaxel and cisplatin as a second-line treatment has a moderate efficacy with an acceptable toxicity in patients with advanced NSCLC.
